KDOQI (Kidney Disease Outcomes Quality Initiative)
NKF KDOQI GUIDELINES

Executive Summaries | Anemia | Hemodialysis | Peritoneal Dialysis |
Vascular Access | Nutrition | CKD 2002 | Dyslipidemias | Bone Metabolism | Hypertension and Antihypertensive Agents | Cardiovascular Disease in Dialysis Patients | History of KDOQI | Pediatric Bone | Anemia 2006 |
Updates 2006

Clinical Practice Guidelines and Clinical Practice Recommendations
2006 Updates
Hemodialysis Adequacy
Peritoneal Dialysis Adequacy
Vascular Access


I.  CLINICAL PRACTICE GUIDELINES FOR HEMODIALYSIS ADEQUACY

REFERENCES

1. Eknoyan G, Beck GJ, Cheung AK, et al: Effect of dialysis dose and membrane flux in maintenance hemodialysis. N Engl J Med 347:2010-2019, 2002

2. Eknoyan G, Levey AS, Beck GJ, et al: The Hemodialysis (HEMO) Study: Rationale for selection of interventions. Semin Dial 9:24-33, 1996

3. Centers for Medicare & Medicaid Services. 2003 Annual Report: End Stage Renal Disease Clinical Performance Measures Project. Am J Kidney Dis 44:S1-S92, 2004 (suppl 1)

4. Consensus Development Conference Panel: Morbidity and mortality of renal dialysis: An NIH consensus conference statement. Ann Intern Med 121:62-70, 1994

5. Renal Physicians Association: Clinical Practice Guideline on Adequacy of Hemodialysis. Washington, DC, Renal Physicians Association, 1993

6. National Kidney Foundation: KDOQI Clinical Practice Guidelines for Hemodialysis Adequacy, 2000. Am J Kidney Dis 37:S7-S64, 2001 (suppl 1)

7. Goodkin DA, Young EW, Kurokawa K, Prutz KG, Levin NW: Mortality among hemodialysis patients in Europe, Japan, and the United States: Case-mix effects. Am J Kidney Dis 44:16-21, 2004

8. Hall YN, Sugihara JG, Go AS, Chertow GM: Differential mortality and transplantation rates among Asians and Pacific Islanders with ESRD. J Am Soc Nephrol 16:3461-3463, 2005

9. Wong JS, Port FK, Hulbert-Shearon TE, et al: Survival advantage in Asian American end-stage renal disease patients. Kidney Int 55:2515-2523, 1999

10. Collins AJ, Kasiske B, Herzog C, et al: Excerpts from the United States Renal Data System 2004 Annual Data Report. Am J Kidney Dis 45, 2005 (suppl 1)

11. Shlipak MG, Massie BM: The clinical challenge of cardiorenal syndrome. Circulation 110:1514-1517, 2004

12. European Best Practice Guidelines Expert Group on Hemodialysis, European Renal Association: Section II. Haemodialysis adequacy. Nephrol Dial Transplant 17:S16-S31, 2002 (suppl 7)

13. Depner T, Daugirdas J, Greene T, et al: Dialysis dose and the effect of gender and body size on outcome in the HEMO Study. Kidney Int 65:1386-1394, 2004

14. Held PJ, Port FK, Wolfe RA, et al: The dose of hemodialysis and patient mortality. Kidney Int 50:550-556, 1996

15. Leggat JE Jr, Orzol SM, Hulbert-Shearon TE, et al: Noncompliance in hemodialysis: Predictors and survival analysis. Am J Kidney Dis 32:139-145, 1998

16. Saran R, Bragg-Gresham JL, Rayner HC, et al: Nonadherence in hemodialysis: Associations with mortality, hospitalization, and practice patterns in the DOPPS. Kidney Int 64:254-262, 2003

17. Plantinga LC, Fink NE, Sadler JH, et al: Frequency of patient-physician contact and patient outcomes in hemodialysis care. J Am Soc Nephrol 15:210-218, 2004

18. Cockcroft DW, Gault MH: Prediction of creatinine clearance from serum creatinine. Nephron 16:31-41, 1976

19. Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D: A more accurate method to estimate glomerular filtration rate from serum creatinine: A new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med 130:461-470, 1999

20. Levey AS, Greene T, Kusek JW, Beck GJ, Group MS: A simplified equation to predict glomerular filtration rate from serum creatinine. J Am Soc Nephrol 11:155A, 2000 (abstr)

21. Schwartz GJ, Brion LP, Spitzer A: The use of plasma creatinine concentration for estimating glomerular filtration rate in infants, children, and adolescents. Pediatr Clin North Am 34:571-590, 1987

22. Stevens LA, Levey AS: Measurement of kidney function. Med Clin North Am 89:457-473, 2005

23. Mohler JL, Barton SD, Blouin RA, Cowen DL, Flanigan RC: The evaluation of creatinine clearance in spinal cord injury patients. J Urol 136:366-369, 1986

24. Gonwa TA, Jennings L, Mai ML, Stark PC, Levey AS, Klintmalm GB: Estimation of glomerular filtration rates before and after orthotopic liver transplantation: Evaluation of current equations. Liver Transpl 10:301-309, 2004

25. Sherman DS, Fish DN, Teitelbaum I: Assessing renal function in cirrhotic patients: Problems and pitfalls. Am J Kidney Dis 41:269-278, 2003

26. Jafar TH, Schmid CH, Levey AS: Serum creatinine as marker of kidney function in South Asians: A study of reduced GFR in adults in Pakistan. J Am Soc Nephrol 16:1413-1419, 2005

27. Moss AH: Shared decision-making in dialysis: The new RPA/ASN guideline on appropriate initiation and withdrawal of treatment. Am J Kidney Dis 37:1081-1091, 2001

28. Galla JH: Clinical practice guideline on shared decision-making in the appropriate initiation of and withdrawal from dialysis. The Renal Physicians Association and the American Society of Nephrology. J Am Soc Nephrol 11:1340-1342, 2000

29. Moss AH: Too many patients who are too sick to benefit start chronic dialysis: Nephrologists need to learn to “just say no.” Am J Kidney Dis 41:723-727, 2003

30. Moss AH, Holley JL, Davison SN, et al: Palliative care. Am J Kidney Dis 43:172-173, 2004

31. Levin A, Lewis M, Mortiboy P, et al: Multidisciplinary predialysis programs: Quantification and limitations of their impact on patient outcomes in two Canadian settings. Am J Kidney Dis 29:533-540, 1997

32. Lopes AA, Bragg J, Young E, et al: Depression as a predictor of mortality and hospitalization among hemodialysis patients in the United States and Europe. Kidney Int 62:199-207, 2002

33. Arora P, Obrador GT, Ruthazer R, et al: Prevalence, predictors, and consequences of late nephrology referral at a tertiary care center. J Am Soc Nephrol 10:1281-1286, 1999

34. Astor BC, Eustace JA, Powe NR, et al: Timing of nephrologist referral and arteriovenous access use: The CHOICE Study. Am J Kidney Dis 38:494-501, 2001

35. Avorn J, Bohn RL, Levy E, et al: Nephrologist care and mortality in patients with chronic renal insufficiency. Arch Intern Med 162:2002-2006, 2002

36. Avorn J, Winkelmayer WC, Bohn RL, et al: Delayed nephrologist referral and inadequate vascular access in patients with advanced chronic kidney failure. J Clin Epidemiol 55:711-716, 2002

37. Levey AS, Coresh J, Balk E, et al: National Kidney Foundation practice guidelines for chronic kidney disease: Evaluation, classification, and stratification. Ann Intern Med 139:137-147, 2003

38. Keshaviah PR, Emerson PF, Nolph KD: Timely initiation of dialysis: A urea kinetic approach. Am J Kidney Dis 33:344-348, 1999

39. Nolph KD: Rationale for early incremental dialysis with continuous ambulatory peritoneal dialysis. Nephrol Dial Transplant 13:S117-S119, 1998 (suppl 6)

40. Tattersall J, Greenwood R, Farrington K: Urea kinetics and when to commence dialysis. Am J Nephrol 15:283-289, 1995

41. US Renal Data System: USRDS 2004 Annual Data Report. The National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, MD, 2004

42. Ellis PA, Reddy V, Bari N, Cairns HS: Late referral of end-stage renal failure. QJM 91:727-732, 1998

43. Ifudu O, Dawood M, Homel P, Friedman EA: Timing of initiation of uremia therapy and survival in patients with progressive renal disease. Am J Nephrol 18:193-198, 1998

44. Roubicek C, Brunet P, Huiart L, et al: Timing of nephrology referral: Influence on mortality and morbidity. Am J Kidney Dis 36:35-41, 2000

45. Sesso R, Belasco AG: Late diagnosis of chronic renal failure and mortality on maintenance dialysis. Nephrol Dial Transplant 11:2417-2420, 1996

46. Fink JC, Burdick RA, Kurth SJ, et al: Significance of serum creatinine values in new end-stage renal disease patients. Am J Kidney Dis 34:694-701, 1999

47. Korevaar JC, Jansen MA, Dekker FW, et al: When to initiate dialysis: Effect of proposed US guidelines on survival. Lancet 358:1046-1050, 2001

48. Traynor JP, Simpson K, Geddes CC, Deighan CJ, Fox JG: Early initiation of dialysis fails to prolong survival in patients with end-stage renal failure. J Am Soc Nephrol 13:2125-2132, 2002

48A. The Renal Association UK Renal Registry. The Sixth Annual Report, Dec. 2003. Accessed May 1, 2006

49. US Renal Data System: USRDS 2003 Annual Data Report. The National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, MD, 2003

50. Curtis BM, Barret BJ, Jindal K, et al: Canadian survey of clinical status at dialysis initiation 1998-1999: A multicenter prospective survey. Clin Nephrol 58:282-288, 2002

51. Cooper BA, Branley P, Bulfone L, et al: The Initiating Dialysis Early and Late (IDEAL) Study: Study rationale and design. Perit Dial Int 24:176-181, 2004

52. National Kidney Foundation: KDOQI Clinical Practice Guidelines for Nutrition in Chronic Renal Failure. Am J Kidney Dis 35:S1-S140, 2000 (suppl 2)

53. Lowrie EG, Laird NM, Parker TF, Sargent JA: Effect of the hemodialysis prescription of patient morbidity: report from the National Cooperative Dialysis Study. N Engl J Med 305:1176-1181, 1981

54. Owen WF Jr, Lew NL, Liu Y, Lowrie EG, Lazarus JM: The urea reduction ratio and serum albumin concentration as predictors of mortality in patients undergoing hemodialysis. N Engl J Med 329:1001-1006, 1993

55. Hakim RM, Breyer J, Ismail N, Schulman G: Effects of dose of dialysis on morbidity and mortality. Am J Kidney Dis 23:661-669, 1994

56. Parker TF III, Husni L, Huang W, Lew N, Lowrie EG: Survival of hemodialysis patients in the United States is improved with a greater quantity of dialysis. Am J Kidney Dis 23:670-680, 1994

57. Owen WF Jr, Chertow GM, Lazarus JM, Lowrie EG: Dose of hemodialysis and survival: Differences by race and sex. JAMA 280:1764-1768, 1998

58. Collins AJ, Ma JZ, Umen A, Keshaviah P: Urea index and other predictors of hemodialysis patient survival. Am J Kidney Dis 23:272-282, 1994

59. Renkin EM, Gilmore JP: Glomerular filtration, in Orloff J, Berliner RW (eds): Handbook of Physiology—Renal Physiology. Washington, DC, American Physiology Society, 1973, pp 185-248

60. Singer MA, Morton AR: Mouse to elephant: Biological scaling and Kt/V. Am J Kidney Dis 35:306-309, 2000

61. Colton CK, Lowrie EG: Physical principles and technical considerations, in Brenner BM, Rector FC (eds): The Kidney. Philadelphia, PA, Saunders, 1981, pp 2425-2489

62. Depner TA: Single-compartment model, in Prescribing Hemodialysis: A Guide to Urea Modeling. Boston, MA, Kluwer, 1991, pp 65-89

63. Daugirdas JT, Greene T, Depner TA, Gotch FA, Star RA: Relationship between apparent (single-pool) and true (double-pool) urea distribution volume. Kidney Int 56:1928-1933, 1999

64. Depner TA: Multi-compartment model, in Prescribing Hemodialysis: A Guide to Urea Modeling. Boston, MA, Kluwer, 1991, pp 91-126

65. Daugirdas JT: Second generation logarithmic estimates of single-pool variable volume Kt/V: An analysis of error. J Am Soc Nephrol 4:1205-1213, 1993

66. Depner TA, Daugirdas JT: Equations for normalized protein catabolic rate based on two-point modeling of hemodialysis urea kinetics. J Am Soc Nephrol 7:780-785, 1996

67. Depner TA: Estimation of Kt/V from the URR for varying levels of dialytic weight loss: A bedside graphic aid. Semin Dial 6:242, 1993

68. Bargman JM, Thorpe KE, Churchill DN: Relative contribution of residual renal function and peritoneal clearance to adequacy of dialysis: A reanalysis of the CANUSA Study. J Am Soc Nephrol 12:2158-2162, 2001

69. Daugirdas JT: Simplified equations for monitoring Kt/V, PCRn, eKt/V, and ePCRn. Adv Ren Replace Ther 2:295-304, 1995

70. Tattersall JE, DeTakats D, Chamney P, Greenwood RN, Farrington K: The post-hemodialysis rebound: Predicting and quantifying its effect on Kt/V. Kidney Int 50:2094-2102, 1996

71. Leypoldt JK, Jaber BL, Zimmerman DL: Predicting treatment dose for novel therapies using urea standard Kt/V. Semin Dial 17:142-145, 2004

72. Held PJ, Levin NW, Bovbjerg RR, Pauly MV, Diamond LH: Mortality and duration of hemodialysis treatment. JAMA 265:871-875, 1991

72A. Saran R, Bragg-Gresham JL, Levin NW, et al: Longer treatment time and slower ultrafiltration in hemodialysis: associations with reduced mortality in the DOPPS. Kidney Int 69:1222-1228, 2006

73. Petitclerc T, Goux N, Reynier AL, Bene B: A model for non-invasive estimation of in vivo dialyzer performances and patient's conductivity during hemodialysis. Int J Artif Organs 16:585-591, 1993

74. Polaschegg HD: On-line dialyser clearance using conductivity. Pediatr Nephrol 9:S9-S11, 1995 (suppl)

75. Di Filippo S, Pozzoni P, Manzoni C, Andrulli S, Pontoriero G, Locatelli F: Relationship between urea clearance and ionic dialysance determined using a single-step conductivity profile. Kidney Int 68:2389-2395, 2005

76. Gotch FA, Panlilio FM, Buyaki RA, Wang EX, Folden TI, Levin NW: Mechanisms determining the ratio of conductivity clearance to urea clearance. Kidney Int Suppl 89:S3-S24, 2004

77. Daugirdas JT, Greene T, Depner TA, Chumlea C, Rocco MJ, Chertow GM: Anthropometrically estimated total body water volumes are larger than modeled urea volume in chronic hemodialysis patients: Effects of age, race, and gender. Kidney Int 64:1108-1119, 2003

78. Lowrie EG, Li Z, Ofsthun N, Lazarus JM: The online measurement of hemodialysis dose (Kt): Clinical outcome as a function of body surface area. Kidney Int 68:1344-1354, 2005

79. Brimble KS, Onge JS, Treleaven DJ, Carlisle EJ: Comparison of volume of blood processed on haemodialysis adequacy measurement sessions vs regular non-adequacy sessions. Nephrol Dial Transplant 17:1470-1474, 2002

80. Lowrie EG, Chertow GM, Lew NL, Lazarus JM, Owen WF: The urea [clearance x dialysis time] product (Kt) as an outcome-based measure of hemodialysis dose. Kidney Int 56:729-737, 1999

81. Termorshuizen F, Dekker FW, van Manen JG, Korevaar JC, Boeschoten EW, Krediet RT: Relative contribution of residual renal function and different measures of adequacy to survival in hemodialysis patients: An analysis of the Netherlands Cooperative Study on the Adequacy of Dialysis (NECOSAD)-2. J Am Soc Nephrol 15:1061-1070, 2004

82. Depner TA: Assessing adequacy of hemodialysis: Urea modeling. Kidney Int 45:1522-1535, 1994

83. Daugirdas JT, Burke MS, Balter P, Priester-Coary A, Majka T: Screening for extreme postdialysis urea rebound using the Smye method: Patients with access recirculation identified when a slow flow method is not used to draw the postdialysis blood. Am J Kidney Dis 28:727-731, 1996

84. Daugirdas JT, Greene T, Depner TA, et al: Factors that affect postdialysis rebound in serum urea concentration, including the rate of dialysis: Results from the HEMO Study. J Am Soc Nephrol 15:194-203, 2004

85. Daugirdas JT, Depner TA, Gotch FA, et al: Comparison of methods to predict equilibrated Kt/V in the HEMO Pilot Study. Kidney Int 52:1395-1405, 1997

86. Jean G, Charra B, Chazot C, Laurent G: Quest for postdialysis urea rebound-equilibrated Kt/V with only intradialytic urea samples. Kidney Int 56:1149-1153, 1999

87. Lew JK, Hutchinson R, Lin ES: Intra-arterial blood sampling for clotting studies. Effects of heparin contamination. Anaesthesia 46:719-721, 1991

88. McLaren G, Hanna C, Mills L, Bourdeau J, Cowin R: Comparison of sampling methods for obtaining accurate coagulation values in hemodialysis patients with heparinized central venous catheters. Nephrol Nurs J 28:632-636, 2001

89. Hakim RM, Depner TA, Parker TF III: Adequacy of hemodialysis. Am J Kidney Dis 20:107-123, 1992

90. Schneditz D, Kaufman AM, Polaschegg HD, Levin NW, Daugirdas JT: Cardiopulmonary recirculation during hemodialysis. Kidney Int 42:1450-1456, 1992

91. Schneditz D, Polaschegg HD, Levin NW, et al: Cardiopulmonary recirculation in dialysis. An underrecognized phenomenon. ASAIO J 38:M194-M196, 1992

92. Cappello A, Grandi F, Lamberti C, Santoro A: Comparative evaluation of different methods to estimate urea distribution volume and generation rate. Int J Artif Organs 17:322-330, 1994

93. Sherman RA: Recirculation revisited. Semin Dial 4:221-223, 1991

94. Schneditz D, Van Stone JC, Daugirdas JT: A regional blood circulation alternative to in-series two compartment urea kinetic modeling. ASAIO J 39:M573-M577, 1993

95. Pedrini LA, Zereik S, Rasmy S: Causes, kinetics and clinical implications of post-hemodialysis urea rebound. Kidney Int 34:817-824, 1988

96. Geddes CC, Traynor J, Walbaum D, Fox JG, Mactier RA: A new method of post-dialysis blood urea sampling: The 'stop dialysate flow' method. Nephrol Dial Transplant 15:517-523, 2000

97. Wu MJ, Feng YF, Shu KH, Cheng CH, Lian JD: Another simpler bypassing dialysate technique for measuring post-haemodialysis BUN. Nephrol Dial Transplant 12:2124-2127, 1997

98. Greene T, Daugirdas J, Depner T, et al: Association of achieved dialysis dose with mortality in the Hemodialysis Study: An example of “dose-targeting bias.” J Am Soc Nephrol 16:3371-3380, 2005

99. Chertow GM, Owen WF, Lazarus JM, Lew NL, Lowrie EG: Exploring the reverse J-shaped curve between urea reduction ratio and mortality. Kidney Int 56:1872-1878, 1999

100. Lowrie EG, Li Z, Ofsthun N, Lazarus JM: Body size, dialysis dose and death risk relationships among hemodialysis patients. Kidney Int 62:1891-1897, 2002

101. Lowrie EG, Li Z, Ofsthun N, Lazarus JM: Measurement of dialyzer clearance, dialysis time, and body size: death risk relationships among patients. Kidney Int 66:2077-2084, 2004

102. Port FK, Ashby VB, Dhingra RK, Roys EC, Wolfe RA: Dialysis dose and body mass index are strongly associated with survival in hemodialysis patients. J Am Soc Nephrol 13:1061-1066, 2002

103. Wolfe RA, Ashby VB, Daugirdas JT, Agodoa LY, Jones CA, Port FK: Body size, dose of hemodialysis, and mortality. Am J Kidney Dis 35:80-88, 2000

104. Port FK, Wolfe RA, Hulbert-Shearon TE, McCullough KP, Ashby VB, Held PJ: High dialysis dose is associated with lower mortality among women but not among men. Am J Kidney Dis 43:1014-1023, 2004

105. Rocco MV, Dwyer JT, Larive B, et al: The effect of dialysis dose and membrane flux on nutritional parameters in hemodialysis patients: Results of the HEMO Study. Kidney Int 65:2321-2334, 2004

106. Unruh M, Benz R, Greene T, et al: Effects of hemodialysis dose and membrane flux on health-related quality of life in the HEMO Study. Kidney Int 66:355-366, 2004

106A. Greene T, Daugirdas J, Beck G, Depner T, Ornt D, Schulman G, Star R, Eknoyan G, and the HEMO Study: Statistical basis for performance standards for achieving a minimum spKt/V goal based on variability observed in the NIH HEMO Study. Proceedings of the XVth International Congress of Nephrology, Buenos Aires, Argentina, 1999, p 419

107. Bleyer AJ, Hylander B, Sudo H, et al: An international study of patient compliance with hemodialysis. JAMA 281:1211-1213, 1999

108. Schrier RW, Gurevich AK, Abraham WT: Renal sodium excretion, edematous disorders, and diuretic use, in Schrier RW (ed): Renal and Electrolyte Disorders. Philadelphia, PA, Lippincott Williams & Wilkins, 2003, pp 64-114

109. Agarwal R, Nissenson AR, Batlle D, Coyne DW, Trout JR, Warnock DG: Prevalence, treatment, and control of hypertension in chronic hemodialysis patients in the United States. Am J Med 115:291-297, 2003

110. Horl MP, Horl WH: Hemodialysis-associated hypertension: Pathophysiology and therapy. Am J Kidney Dis 39:227-244, 2002

111. Rocco MV, Yan G, Heyka RJ, Benz R, Cheung AK: Risk factors for hypertension in chronic hemodialysis patients: Baseline data from the HEMO Study. Am J Nephrol 21:280-288, 2001

112. Wilson J, Shah T, Nissenson AR: Role of sodium and volume in the pathogenesis of hypertension in hemodialysis. Semin Dial 17:260-264, 2004

113. Foley RN, Herzog CA, Collins AJ: Blood pressure and long-term mortality in United States hemodialysis patients: USRDS Waves 3 and 4 Study. Kidney Int 62:1784-1790, 2002

114. De Lorenzo A, Deurenberg P, Andreoli A, Sasso GF, Palestini M, Docimo R: Multifrequency impedance in the assessment of body water losses during dialysis. Ren Physiol Biochem 17:326-332, 1994

115. Sherman RA: Modifying the dialysis prescription to reduce intradialytic hypotension. Am J Kidney Dis 38:S18-S25, 2001 (suppl 4)

116. Mitch WE, Wilcox CS: Disorders of body fluids, sodium and potassium in chronic renal failure. Am J Med 72:536-550, 1982

117. Dorhout Mees EJ, Ozbash C, Akcicek F: Cardiovascular disturbances in hemodialysis patients: The importance of volume overload. J Nephrol 8:71-78, 1995

118. Koomans HA, Geers AB, Mees EJ: Plasma volume recovery after ultrafiltration in patients with chronic renal failure. Kidney Int 26:848-854, 1984

119. Chazot C, Charra B, Vo Van C, et al: The Janus-faced aspect of 'dry weight.' Nephrol Dial Transplant 14:121-124, 1999

120. Zucchelli P, Santoro A, Zuccala A: Genesis and control of hypertension in hemodialysis patients. Semin Nephrol 8:163-168, 1988

121. Mailloux LU, Fields S, Campese VM: Hypertension in chronic dialysis patients, in Nissenson AR, Fine RN (eds): Dialysis Therapy. Philadelphia, PA, Hanley & Belfus, 2002, pp 341-358

122. Charra B, Bergstrom J, Scribner BH: Blood pressure control in dialysis patients: Importance of the lag phenomenon. Am J Kidney Dis 32:720-724, 1998

123. D'Amico M, Locatelli F: Hypertension in dialysis: Pathophysiology and treatment. J Nephrol 15:438-445, 2002

124. Fishbane SA, Scribner BH: Blood pressure control in dialysis patients. Semin Dial 15:144-145, 2002

125. Comty C, Rottka H, Shaldon S: Blood pressure control in patients with end-stage renal failure treated by intermittent haemodialysis. Proc Eur Dial Transplant Assoc 1:209-213, 1964

126. Campese VM, Tanasescu A: Hypertension in dialysis patients, in Henrich WL (ed): Principles and Practice of Dialysis (ed 3). Philadelphia, PA, Lippincott Williams & Wilkins, 2004, pp 227-256

127. Jabara AE, Mehta RL: Determination of fluid shifts during chronic hemodialysis using bioimpedance spectroscopy and an in-line hematocrit monitor. ASAIO J 41:M682-M687, 1995

128. Leypoldt JK, Cheung AK, Steuer RR, Harris DH, Conis JM: Determination of circulating blood volume by continuously monitoring hematocrit during hemodialysis. J Am Soc Nephrol 6:214-219, 1995

129. Rodriguez HJ, Domenici R, Diroll A, Goykhman I: Assessment of dry weight by monitoring changes in blood volume during hemodialysis using Crit-Line. Kidney Int 68:854-861, 2005

130. Goldstein SL, Patel HP, Mahan JD, Flynn JT: Prospective evaluation of a non-invasive monitoring of hematocrit (NIVM) algorithm to improve cardiovascular (CV) parameters in pediatric (ped) hemodialysis (HD) patients (Pt). J Am Soc Nephrol 16:725A, 2005 (abstr)

131. Reddan DN, Szczech LA, Hasselblad V, et al: Intradialytic blood volume monitoring in ambulatory hemodialysis patients: A randomized trial. J Am Soc Nephrol 16:2162-2169, 2005

132. Schneditz D, Zaluska WT, Morris AT, Levin NW: Effect of ultrafiltration on peripheral urea sequestration in haemodialysis patients. Nephrol Dial Transplant 16:994-998, 2001

133. Charra B, Terrat JC, Vanel T, et al: Long thrice weekly hemodialysis: The Tassin experience. Int J Artif Organs 27:265-283, 2004

134. Salem M: Hypertension in the hemodialysis population? High time for answers. Am J Kidney Dis 33:592-594, 1999

135. Raine AE, Margreiter R, Brunner FP, et al: Report on management of renal failure in Europe, XXII, 1991. Nephrol Dial Transplant 7:S7-S35, 1992 (suppl 2)

136. Grekas D, Bamichas G, Bacharaki D, Goutzaridis N, Kasimatis E, Tourkantonis A: Hypertension in chronic hemodialysis patients: Current view on pathophysiology and treatment. Clin Nephrol 53:164-168, 2000

137. Levey AS, Eknoyan G: Cardiovascular disease in chronic renal disease. Nephrol Dial Transplant 14:828-833, 1999

138. Mittal SK, Kowalski E, Trenkle J, et al: Prevalence of hypertension in a hemodialysis population. Clin Nephrol 51:77-82, 1999

139. Cheigh JS, Milite C, Sullivan JF, Rubin AL, Stenzel KH: Hypertension is not adequately controlled in hemodialysis patients. Am J Kidney Dis 19:453-459, 1992

140. Scribner BH: A personalized history of chronic hemodialysis. Am J Kidney Dis 16:511-519, 1990

141. Shaldon S: What clinical insights from the early days of dialysis are being overlooked today? Semin Dial 18:18-19, 2005

142. Cohen EP: Dialysis hypertension: Dry weight and dialysis time. Nephrol Dial Transplant 13:554-555, 1998

143. Charra B, Chazot C: The neglect of sodium restriction in dialysis patients: A short review. Hemodial Int 7:342-347, 2003

144. Flanigan M: Dialysate composition and hemodialysis hypertension. Semin Dial 17:279-283, 2004

145. Stiller S, Bonnie-Schorn E, Grassmann A, Uhlenbusch-Korwer I, Mann H: A critical review of sodium profiling for hemodialysis. Semin Dial 14:337-347, 2001

146. Agarwal R: Hypertension in hemodialysis, in Nissenson AR, Fine RN (eds): Clinical Dialysis (ed 4). New York, NY, McGraw-Hill, 2005, pp 755-769

147. Zoccali C, Dunea G: Hypertension, in Daugirdas JT, Blake PG, Ing TS (eds): Handbook of Dialysis. Philadelphia, PA, Lippincott Williams & Wilkins, 2001, pp 466-476

148. Foley RN, Parfrey PS, Harnett JD, Kent GM, Murray DC, Barre PE: Impact of hypertension on cardiomyopathy, morbidity and mortality in end-stage renal disease. Kidney Int 49:1379-1385, 1996

149. Collins AJ: Cardiovascular mortality in end-stage renal disease. Am J Med Sci 325:163-167, 2003

150. Luik AJ, Kooman JP, Leunissen KM: Hypertension in haemodialysis patients: Is it only hypervolaemia? Nephrol Dial Transplant 12:1557-1560, 1997

151. Blacher J, Guerin AP, Pannier B, Marchais SJ, Safar ME, London GM: Impact of aortic stiffness on survival in end-stage renal disease. Circulation 99:2434-2439, 1999

152. Klassen PS, Lowrie EG, Reddan DN, et al: Association between pulse pressure and mortality in patients undergoing maintenance hemodialysis. JAMA 287:1548-1555, 2002

153. Fujiwara N, Osanai T, Kamada T, Katoh T, Takahashi K, Okumura K: Study on the relationship between plasma nitrite and nitrate level and salt sensitivity in human hypertension: Modulation of nitric oxide synthesis by salt intake. Circulation 101:856-861, 2000

154. MacAllister RJ, Rambausek MH, Vallance P, Williams D, Hoffmann KH, Ritz E: Concentration of dimethyl-L-arginine in the plasma of patients with end-stage renal failure. Nephrol Dial Transplant 11:2449-2452, 1996

155. Vallance P, Leone A, Calver A, Collier J, Moncada S: Accumulation of an endogenous inhibitor of nitric oxide synthesis in chronic renal failure. Lancet 339:572-575, 1992

156. Converse RL Jr, Jacobsen TN, Toto RD, et al: Sympathetic overactivity in patients with chronic renal failure. N Engl J Med 327:1912-1918, 1992

157. Agarwal R, Lewis R, Davis JL, Becker B: Lisinopril therapy for hemodialysis hypertension: Hemodynamic and endocrine responses. Am J Kidney Dis 38:1245-1250, 2001

158. Abraham PA, Macres MG: Blood pressure in hemodialysis patients during amelioration of anemia with erythropoietin. J Am Soc Nephrol 2:927-936, 1991

159. Agarwal R: Hypertension and survival in chronic hemodialysis patients—Past lessons and future opportunities. Kidney Int 67:1-13, 2005

160. London G, Marchais S, Guerin AP: Blood pressure control in chronic hemodialysis patients, in Jacob C, Kjellstrand CM, Koch KM, Winchester JF (eds): Replacement of Renal Function by Dialysis. Dordrecht, The Netherlands, Kluwer, 1996, pp 966-989

161. Agarwal R: Exploring the paradoxical relationship of hypertension with mortality in chronic hemodialysis. Hemodial Int 8:207-213, 2004

162. Schomig M, Eisenhardt A, Ritz E: Controversy on optimal blood pressure on haemodialysis: Normotensive blood pressure values are essential for survival. Nephrol Dial Transplant 16:469-474, 2001

163. Zager PG, Nikolic J, Brown RH, et al: “U” Curve association of blood pressure and mortality in hemodialysis patients. Medical Directors of Dialysis Clinic, Inc. Kidney Int 54:561-569, 1998

164. Port FK, Hulbert-Shearon TE, Wolfe RA, et al: Predialysis blood pressure and mortality risk in a national sample of maintenance hemodialysis patients. Am J Kidney Dis 33:507-517, 1999

165. Scribner BH: Can antihypertensive medications control BP in haemodialysis patients: Yes or no? Nephrol Dial Transplant 14:2599-2601, 1999

166. Levin NW, Blagg CR, Twardowski ZJ, Shaldon S, Bower JD: What clinical insights from the early days of dialysis are being overlooked today? Semin Dial 18:13-15, 2005

167. Cirit M, Akcicek F, Terzioglu E, et al: 'Paradoxical' rise in blood pressure during ultrafiltration in dialysis patients. Nephrol Dial Transplant 10:1417-1420, 1995

168. Eaton SB, Konner M: Paleolithic nutrition. A consideration of its nature and current implications. N Engl J Med 312:283-289, 1985

169. Appel LJ, Brands MW, Daniels SR, Karanja N, Elmer PJ, Sacks FM: Dietary approaches to prevent and treat hypertension: A scientific statement from the American Heart Association. Hypertension 47:296-308, 2006

170. Krauss RM, Deckelbaum RJ, Ernst N, et al: Dietary guidelines for healthy American adults. A statement for health professionals from the Nutrition Committee, American Heart Association. Circulation 94:1795-1800, 1996

171. Dietary Reference Intakes: Water, Potassium, Sodium, Chloride and Sulfate. Washington, DC, Institute of Medicine, National Academy Press, 2004

172. 2003 European Society of Hypertension-European Society of Cardiology: Guidelines for the management of arterial hypertension. J Hypertens 21:1011-1053, 2003

173. Sacks FM, Svetkey LP, Vollmer WM, et al: Effects on blood pressure of reduced dietary sodium and the Dietary Approaches to Stop Hypertension (DASH) diet. DASH-Sodium Collaborative Research Group. N Engl J Med 344:3-10, 2001

174. Khosla UM, Johnson RJ: Hypertension in the hemodialysis patient and the “lag phenomenon”: Insights into pathophysiology and clinical management. Am J Kidney Dis 43:739-751, 2004

175. Krautzig S, Janssen U, Koch KM, Granolleras C, Shaldon S: Dietary salt restriction and reduction of dialysate sodium to control hypertension in maintenance haemodialysis patients. Nephrol Dial Transplant 13:552-553, 1998

176. Rostand SG, Rutsky EA: Cardiac disease in dialysis patients, in Nissenson AR, Fine RN, Gentile DE (eds): Clinical Dialysis. Norwalk, CT, Appleton & Lange, 1995, pp 652-698

176A. Kaplan NM: Patient information. Hypertension and diet and weight. UpToDate, version 13.3, UptoDate Inc., Waltham, MA, September 2005

177. Mattes RD: The taste for salt in humans. Am J Clin Nutr 65:S692-S697, 1997 (suppl 2)

178. Korhonen MH, Jarvinen RM, Sarkkinen ES, Uusitupa MI: Effects of a salt-restricted diet on the intake of other nutrients. Am J Clin Nutr 72:414-420, 2000

179. Kempner W: Treatment of hypertensive vascular disease with rice diet. Am J Med 8:545-577, 1948

180. Carvalho JJ, Baruzzi RG, Howard PF, et al: Blood pressure in four remote populations in the INTERSALT Study. Hypertension 14:238-246, 1989

181. Ahmad S: Dietary sodium restriction for hypertension in dialysis patients. Semin Dial 17:284-287, 2004

182. Blumberg A, Nelp WB, Hegstrom RM, Scribner BH: Extracellular volume in patients with chronic renal disease treated for hypertension by sodium restriction. Lancet 2:69-73, 1967

183. Mailloux LU: The overlooked role of salt restriction in dialysis patients. Semin Dial 13:150-151, 2000

184. Maduell F, Navarro V: Dietary salt intake and blood pressure control in haemodialysis patients. Nephrol Dial Transplant 15:2063, 2000

185. Ozkahya M, Toz H, Qzerkan F, et al: Impact of volume control on left ventricular hypertrophy in dialysis patients. J Nephrol 15:655-660, 2002

186. Shaldon S: Dietary salt restriction and drug-free treatment of hypertension in ESRD patients: A largely abandoned therapy. Nephrol Dial Transplant 17:1163-1165, 2002

187. Shaldon S: Salt restriction and not length of dialysis is the key to drug free blood pressure control in ESRD patients. J Nephrol 16:159, 2003

188. Shaldon S: Is salt restriction more important than the length of dialysis in the miracle of Tassin? Int J Artif Organs 27:813-814; author reply 27:815, 2004

189. Hegstrom RM, Murray JS, Pendras JP, Burnell JM, Scribner BH: Two year's experience with periodic hemodialysis in the treatment of chronic uremia. Trans Am Soc Artif Intern Organs 8:266-280, 1962

190. Shaldon S, Rae AI, Rosen SM, Silva H, Oakley J: Refrigerated femoral venous-venous haemodialysis with coil preservation for rehabilitation of terminal uraemic patients. Br Med J 5347:1716-1717, 1963

191. Scribner BH: Adequate control of blood pressure in patients on chronic hemodialysis. Kidney Int 41:1286, 1992

192. Abuelo JG: Large interdialytic weight gain. Causes, consequences and corrective measures. Semin Dial 11:25-32, 1998

193. Kempner W: Treatment of kidney disease and hypertensive disease with rice diet. N C Med J 5:125-133, 1944

194. Kempner W: Treatment of heart and kidney disease and of hypertensive and arteriosclerotic vascular disease with the rice diet. Ann Intern Med 31:821-856, 1949

195. Gunal AI, Duman S, Ozkahya M, et al: Strict volume control normalizes hypertension in peritoneal dialysis patients. Am J Kidney Dis 37:588-593, 2001

196. Ritz E: Salt—Friend or foe? Nephrol Dial Transplant Dec 29, 2005

197. Charra B, Calemard E, Ruffet M, et al: Survival as an index of adequacy of dialysis. Kidney Int 41:1286-1291, 1992

198. Innes A, Charra B, Burden RP, Morgan AG, Laurent G: The effect of long, slow haemodialysis on patient survival. Nephrol Dial Transplant 14:919-922, 1999

199. Ozkahya M, Ok E, Cirit M, et al: Regression of left ventricular hypertrophy in haemodialysis patients by ultrafiltration and reduced salt intake without antihypertensive drugs. Nephrol Dial Transplant 13:1489-1493, 1998

200. Ayus JC, Mizani MR, Achinger SG, Thadhani R, Go AS, Lee S: Effects of short daily versus conventional hemodialysis on left ventricular hypertrophy and inflammatory markers: A prospective, controlled study. J Am Soc Nephrol 16:2778-2788, 2005

201. Buoncristiani U: Fifteen years of clinical experience with daily haemodialysis. Nephrol Dial Transplant 13:S148-S151, 1998 (suppl 6)

202. Depner TA: Why daily hemodialysis is better: Solute kinetics. Semin Dial 12:462-471, 1999

203. Alloatti S, Molino A, Manes M, Bonfant G, Pellu V: Long nocturnal dialysis. Blood Purif 20:525-530, 2002

204. Lockridge RS Jr, Spencer M, Craft V, et al: Nocturnal home hemodialysis in North America. Adv Ren Replace Ther 8:250-256, 2001

205. Pierratos A, Ouwendyk M, Francoeur R, et al: Nocturnal hemodialysis: Three-year experience. J Am Soc Nephrol 9:859-868, 1998

206. Brunet P, Saingra Y, Leonetti F, Vacher-Coponat H, Ramananarivo P, Berland Y: Tolerance of haemodialysis: A randomized cross-over trial of 5-h versus 4-h treatment time. Nephrol Dial Transplant 11:S46-S51, 1996 (suppl 8)

207. Tomson CR: Advising dialysis patients to restrict fluid intake without restricting sodium intake is not based on evidence and is a waste of time. Nephrol Dial Transplant 16:1538-1542, 2001

208. Rigby AJ, Scribner BH, Ahmad S: Sodium, not fluid, controls interdialytic weight gain. Nephrol News Issues 14:21-22, 2000

209. Feinstein EI: Nutritional therapy in maintenance hemodialysis, in Nissenson AR, Fine RN (eds): Dialysis Therapy. Philadelphia, PA, Hanley & Belfus, 2002, pp 281-285

210. Campese VM, Mozayeni P, Ye S, Gumbard M: High salt intake inhibits nitric oxide synthase expression and aggravates hypertension in rats with chronic renal failure. J Nephrol 15:407-413, 2002

211. Hamlyn JM, Hamilton BP, Manunta P: Endogenous ouabain, sodium balance and blood pressure: A review and a hypothesis. J Hypertens 14:151-167, 1996

212. Luik AJ, Charra B, Katzarski K, et al: Blood pressure control and hemodynamic changes in patients on long time dialysis treatment. Blood Purif 16:197-209, 1998

213. Dunn CJ, Fitton A, Brogden RN: Torasemide. An update of its pharmacological properties and therapeutic efficacy. Drugs 49:121-142, 1995

214. Flamenbaum W, Friedman R: Pharmacology, therapeutic efficacy, and adverse effects of bumetanide, a new “loop” diuretic. Pharmacotherapy 2:213-222, 1982

215. Medcalf JF, Harris KP, Walls J: Role of diuretics in the preservation of residual renal function in patients on continuous ambulatory peritoneal dialysis. Kidney Int 59:1128-1133, 2001

216. Wilcox CS: New insights into diuretic use in patients with chronic renal disease. J Am Soc Nephrol 13:798-805, 2002

217. Khandelwal M, Oreopoulos DG: Is there a need for low sodium dialysis solution for peritoneal dialysis patients? Adv Perit Dial 20:156-162, 2004

218. Schwartz GH, David DS, Riggio RR, Stenzel KH, Rubin AL: Ototoxicity induced by furosemide. N Engl J Med 282:1413-1414, 1970

219. Humes HD: Insights into ototoxicity. Analogies to nephrotoxicity. Ann N Y Acad Sci 884:15-18, 1999

220. Van Stone JC, Bauer J, Carey J: The effect of dialysate sodium concentration on body fluid compartment volume, plasma renin activity and plasma aldosterone concentration in chronic hemodialysis patients. Am J Kidney Dis 2:58-64, 1982

221. Locatelli F, Di Filippo S, Pontoriero G: Fluid and electrolyte balance during extracorporeal therapies, in Ronco C, Bellomo R (eds): Critical Care Nephrology. Dordrecht, The Netherlands, Kluwer, 1998, pp 249-259

222. Mann H, Stiller S: Urea, sodium, and water changes in profiling dialysis. Nephrol Dial Transplant 11:S10-S15, 1996 (suppl 8)

223. Sang GL, Kovithavongs C, Ulan R, Kjellstrand CM: Sodium ramping in hemodialysis: A study of beneficial and adverse effects. Am J Kidney Dis 29:669-677, 1997

224. Horl MP, Horl WH: Drug therapy for hypertension in hemodialysis patients. Semin Dial 17:288-294, 2004

225. Menon MK, Naimark DM, Bargman JM, Vas SI, Oreopoulos DG: Long-term blood pressure control in a cohort of peritoneal dialysis patients and its association with residual renal function. Nephrol Dial Transplant 16:2207-2213, 2001

226. Shin SK, Noh H, Kang SW, et al: Risk factors influencing the decline of residual renal function in continuous ambulatory peritoneal dialysis patients. Perit Dial Int 19:138-142, 1999

227. Singhal MK, Bhaskaran S, Vidgen E, Bargman JM, Vas SI, Oreopoulos DG: Rate of decline of residual renal function in patients on continuous peritoneal dialysis and factors affecting it. Perit Dial Int 20:429-438, 2000

228. Lysaght MJ, Vonesh EF, Gotch F, et al: The influence of dialysis treatment modality on the decline of remaining renal function. ASAIO Trans 37:598-604, 1991

229. McKane W, Chandna SM, Tattersall JE, Greenwood RN, Farrington K: Identical decline of residual renal function in high-flux biocompatible hemodialysis and CAPD. Kidney Int 61:256-265, 2002

230. Moist LM, Port FK, Orzol SM, et al: Predictors of loss of residual renal function among new dialysis patients. J Am Soc Nephrol 11:556-564, 2000

231. Van Stone JC: The effect of dialyzer membrane and etiology of kidney disease on the preservation of residual renal function in chronic hemodialysis patients. ASAIO J 41:M713-M716, 1995

232. Schiffl H, Lang SM, Fischer R: Ultrapure dialysis fluid slows loss of residual renal function in new dialysis patients. Nephrol Dial Transplant 17:1814-1818, 2002

233. National Kidney Foundation: KDOQI Clinical Practice Guidelines for Peritoneal Dialysis Adequacy, 2000. Am J Kidney Dis 37:S65-S136, 2001 (suppl 1)

234. Hanson JA, Hulbert-Shearon TE, Ojo AO, et al: Prescription of twice-weekly hemodialysis in the USA. Am J Nephrol 19:625-633, 1999

235. Depner TA: Daily hemodialysis efficiency: An analysis of solute kinetics. Adv Ren Replace Ther 8:227-235, 2001

236. Sugarman JR, Frederick PR, Frankenfield DL, Owen WF Jr, McClellan WM: Developing clinical performance measures based on the Dialysis Outcomes Quality Initiative Clinical Practice Guidelines: Process, outcomes, and implications. Am J Kidney Dis 42:806-812, 2003

236A. Healthy People 2010. Accessed May 1, 2006

237. Owen WF Jr: Patterns of care for patients with chronic kidney disease in the United States: Dying for improvement. J Am Soc Nephrol 14:S76-S80, 2003 (suppl 2)

237A. Available at: www.clinicaltrials.gov/show/NCT00264758. Accessed May 1, 2006

238. Collins AJ, Liu J, Ebben JP: Dialyser reuse-associated mortality and hospitalization risk in incident Medicare haemodialysis patients, 1998-1999. Nephrol Dial Transplant 19:1245-1251, 2004

239. Robinson BM, Feldman HI: Dialyzer reuse and patient outcomes: What do we know now? Semin Dial 18:175-179, 2005

240. Hays RD, Kallich JD, Mapes DL, Coons SJ, Carter WB: Development of the Kidney Disease Quality of Life (KDQOL) instrument. Qual Life Res 3:329-338, 1994

241. DeOreo PB: Hemodialysis patient-assessed functional health status predicts continued survival, hospitalization, and dialysis-attendance compliance. Am J Kidney Dis 30:204-212, 1997

242. Kalantar-Zadeh K, Kopple JD, Block G, Humphreys MH: Association among SF36 quality of life measures and nutrition, hospitalization, and mortality in hemodialysis. J Am Soc Nephrol 12:2797-2806, 2001

243. Mapes DL, Lopes AA, Satayathum S, et al: Health-related quality of life as a predictor of mortality and hospitalization: The Dialysis Outcomes and Practice Patterns Study (DOPPS). Kidney Int 64:339-349, 2003

244. Bakewell AB, Higgins RM, Edmunds ME: Does ethnicity influence perceived quality of life of patients on dialysis and following renal transplant? Nephrol Dial Transplant 16:1395-1401, 2001

245. Hicks LS, Cleary PD, Epstein AM, Ayanian JZ: Differences in health-related quality of life and treatment preferences among black and white patients with end-stage renal disease. Qual Life Res 13:1129-1137, 2004

246. Kutner NG, Brogan D, Fielding B, Hall WD: Black/white differences in symptoms and health satisfaction reported by older hemodialysis patients. Ethn Dis 10:328-333, 2000

247. Unruh M, Miskulin D, Yan G, et al: Racial differences in health-related quality of life among hemodialysis patients. Kidney Int 65:1482-1491, 2004

248. Bass EB, Wills S, Fink NE, et al: How strong are patients' preferences in choices between dialysis modalities and doses? Am J Kidney Dis 44:695-705, 2004

249. Ayanian JZ, Cleary PD, Keogh JH, Noonan SJ, David-Kasdan JA, Epstein AM: Physicians' beliefs about racial differences in referral for renal transplantation. Am J Kidney Dis 43:350-357, 2004

250. Ayanian JZ, Cleary PD, Weissman JS, Epstein AM: The effect of patients' preferences on racial differences in access to renal transplantation. N Engl J Med 341:1661-1669, 1999

251. Seikaly MG, Loleh S, Rosenblum A, Browne R: Validation of the Center for Medicare and Medicaid Services algorithm for eligibility for dialysis. Pediatr Nephrol 19:893-897, 2004

252. Goldstein SL: Hemodialysis in the pediatric patient: State of the art. Adv Ren Replace Ther 8:173-179, 2001

253. Marsenic O, Peco-Antic A, Jovanovic O: Effect of dialysis dose on nutritional status of children on chronic hemodialysis. Nephron 88:273-275, 2001

254. Goldstein SL, Baronette S, Gambrell TV, Currier H, Brewer ED: nPCR assessment and IDPN treatment of malnutrition in pediatric hemodialysis patients. Pediatr Nephrol 17:531-534, 2002

255. Orellana P, Juarez-Congelosi M, Goldstein SL: Intradialytic parenteral nutrition treatment and biochemical marker assessment for malnutrition in adolescent maintenance hemodialysis patients. J Ren Nutr 15:312-317, 2005

256. Goldstein SL, Brewer ED: Logarithmic extrapolation of a 15-minute postdialysis BUN to predict equilibrated BUN and calculate double-pool Kt/V in the pediatric hemodialysis population. Am J Kidney Dis 36:98-104, 2000

257. Tom A, McCauley L, Bell L, et al: Growth during maintenance hemodialysis: Impact of enhanced nutrition and clearance. J Pediatr 134:464-471, 1999

258. Goldstein SL, Currier H, Watters L, Hempe JM, Sheth RD, Silverstein D: Acute and chronic inflammation in pediatric patients receiving hemodialysis. J Pediatr 143:653-657, 2003

259. Frankenfield DL, Neu AM, Warady BA, Watkins SL, Friedman AL, Fivush BA: Adolescent hemodialysis: results of the 2000 ESRD Clinical Performance Measures Project. Pediatr Nephrol 17:10-15, 2002

260. Goldstein SL, Smith CM, Currier H: Noninvasive interventions to decrease hospitalization and associated costs for pediatric patients receiving hemodialysis. J Am Soc Nephrol 14:2127-2131, 2003

261. Jain SR, Smith L, Brewer ED, Goldstein SL: Non-invasive intravascular monitoring in the pediatric hemodialysis population. Pediatr Nephrol 16:15-18, 2001

262. Michael M, Brewer ED, Goldstein SL: Blood volume monitoring to achieve target weight in pediatric hemodialysis patients. Pediatr Nephrol 19:432-437, 2004

263. Levey AS, Greene T, Schluchter MD, et al: Glomerular filtration rate measurements in clinical trials. Modification of Diet in Renal Disease Study Group and the Diabetes Control and Complications Trial Research Group. J Am Soc Nephrol 4:1159-1171, 1993

264. Casino FG, Lopez T: The equivalent renal urea clearance: A new parameter to assess dialysis dose. Nephrol Dial Transplant 11:1574-1581, 1996

265. Gotch FA: The current place of urea kinetic modelling with respect to different dialysis modalities. Nephrol Dial Transplant 13:S10-S14, 1998 (suppl 6)

266. Keshaviah PR, Nolph KD, Van Stone JC: The peak concentration hypothesis: A urea kinetic approach to comparing the adequacy of continuous ambulatory peritoneal dialysis (CAPD) and hemodialysis. Perit Dial Int 9:257-260, 1989

267. Depner TA: Benefits of more frequent dialysis: Lower TAC at the same Kt/V. Nephrol Dial Transplant 13:S20-S24, 1998 (suppl 6)

268. Depner TA, Bhat A: Quantifying daily hemodialysis. Semin Dial 17:79-84, 2004

269. Watson PE, Watson ID, Batt RD: Total body water volumes for adult males and females estimated from simple anthropometric measurements. Am J Clin Nutr 33:27-39, 1980

270. Cheung AK, Levin NW, Greene T, et al: Effects of high-flux hemodialysis on clinical outcomes: Results of the HEMO Study. J Am Soc Nephrol 14:3251-3263, 2003

271. Cheung AK, Sarnak MJ, Yan G, et al: Cardiac diseases in maintenance hemodialysis patients: Results of the HEMO Study. Kidney Int 65:2380-2389, 2004

272. Locatelli F, Andrulli S, Pecchini F, et al: Effect of high-flux dialysis on the anaemia of haemodialysis patients [see comment]. Nephrol Dial Transplant 15:1399-1409, 2000

273. MacLeod AM, Campbell M, Cody JD, et al: Cellulose, modified cellulose and synthetic membranes in the haemodialysis of patients with end-stage renal disease. Cochrane Database Syst Rev CD003234, 2005

274. Leypoldt JK, Cheung AK, Carroll CE, et al: Effect of dialysis membranes and middle molecule removal on chronic hemodialysis patient survival. Am J Kidney Dis 33:349-355, 1999

275. Woods HF, Nandakumar M: Improved outcome for haemodialysis patients treated with high-flux membranes. Nephrol Dial Transplant 15:S36-S42, 2000 (suppl 1)

276. Schiffl H, Fischer R, Lang SM, Mangel E: Clinical manifestations of AB-amyloidosis: Effects of biocompatibility and flux. Nephrol Dial Transplant 15:840-845, 2000

277. Leypoldt JK, Cheung AK, Deeter RB: Rebound kinetics of beta2-microglobulin after hemodialysis. Kidney Int 56:1571-1577, 1999

277A. Ebben JP, Liu J, Collins AJ: Membrane associated morbidity in incident and prevalent hemodialysis patients. J Am Soc Nephrol 13:614A, 2002 (abstr)

278. Locatelli F, Marcelli D, Conte F, Limido A, Malberti F, Spotti D: Comparison of mortality in ESRD patients on convective and diffusive extracorporeal treatments. The Registro Lombardo Dialisi E Trapianto. Kidney Int 55:286-293, 1999

279. European Best Practice Guidelines for Haemodialysis (Part 1): Section III. Biocompatibility. Nephrol Dial Transplant 17:S32-S44, 2002 (suppl 7)

280. Locatelli F, Mastrangelo F, Redaelli B, et al: Effects of different membranes and dialysis technologies on patient treatment tolerance and nutritional parameters. The Italian Cooperative Dialysis Study Group. Kidney Int 50:1293-1302, 1996

281. Nakai S, Iseki K, Tabei K, et al: Outcomes of hemodiafiltration based on Japanese dialysis patient registry. Am J Kidney Dis 38:S212-S216, 2001 (suppl 1)

282. van Ypersele de Strihou C, Jadoul M, Malghem J, Maldague B, Jamart J: Effect of dialysis membrane and patient's age on signs of dialysis-related amyloidosis. The Working Party on Dialysis Amyloidosis. Kidney Int 39:1012-1019, 1991

283. Twardowski Z: Effect of long-term increase in the frequence and/or prolongation of dialysis duration on certain clinical manifestations and results of laboratory investigations in patients with chronic renal failure. Acta Med Pol 16:31-44, 1975

284. Pierratos A, McFarlane P, Chan CT: Quotidian dialysis—Update 2005. Curr Opin Nephrol Hypertens 14:119-124, 2005

285. Diaz-Buxo JA: Beyond thrice-weekly hemodialysis. Hemodial Int 9:309-313, 2005

286. Block GA, Klassen PS, Lazarus JM, Ofsthun N, Lowrie EG, Chertow GM: Mineral metabolism, mortality, and morbidity in maintenance hemodialysis. J Am Soc Nephrol 15:2208-2218, 2004

287. Salahudeen AK, Dykes P, May W: Risk factors for higher mortality at the highest levels of spKt/V in hemodialysis patients. Nephrol Dial Transplant 18:1339-1344, 2003

288. Kopple JD, Greene T, Chumlea WC, et al: Relationship between nutritional status and the glomerular filtration rate: Results from the MDRD Study. Kidney Int 57:1688-1703, 2000

289. Velasquez MT, von Albertini B, Lew SQ, Mishkin GJ, Bosch JP: Equal levels of blood pressure control in ESRD patients receiving high-efficiency hemodialysis and conventional hemodialysis. Am J Kidney Dis 31:618-623, 1998

290. Kurella M, Chertow GM: Dialysis session length (“t”) as a determinant of the adequacy of dialysis. Semin Nephrol 25:90-95, 2005

291. Association for Advancement of Medical Information (AAMI): American National Standard. Reuse of Hemodialyzers (ANSI/AAMI RD47:2002 & RD47:2002/A1:2003). Arlington, VA, AAMI, 2003

292. National Kidney Foundation: Report on dialyzer reuse. Task Force on Reuse of Dialyzers, Council on Dialysis, National Kidney Foundation. Am J Kidney Dis 30:859-871, 1997

293. Agodoa LY, Wolfe RA, Port FK: Reuse of dialyzers and clinical outcomes: Fact or fiction. Am J Kidney Dis 32:S88-S92, 1998 (suppl 4)

294. Clark WR, Scott MK, Leypoldt JK: Reuse of dialyzers: Methods and complications of dialyzer reuse, in Nissenson AR, Fine RN (eds): Dialysis Therapy. Philadelphia, PA, Hanley & Belfus, 2002, pp 199-203

295. Finelli L, Miller JT, Tokars JI, Alter MJ, Arduino MJ: National surveillance of dialysis-associated diseases in the United States, 2002. Semin Dial 18:52-61, 2005

296. Light PD: Reuse of hemodialysis membranes in chronic dialysis therapy, in Henrich WL (ed): Principles and Practice of Dialysis (ed 3). Philadelphia, PA, Lippincott Williams & Wilkins, 2004, pp 16-27

297. Port FK, Wolfe RA, Hulbert-Shearon TE, et al: Mortality risk by hemodialyzer reuse practice and dialyzer membrane characteristics: Results from the USRDS Dialysis Morbidity and Mortality Study. Am J Kidney Dis 37:276-286, 2001

298. Vinhas J, Pinto dos Santos J: Haemodialyser reuse: Facts and fiction. Nephrol Dial Transplant 15:5-8, 2000

299. Lowrie EG, Li Z, Ofsthun N, Lazarus JM: Reprocessing dialysers for multiple uses: Recent analysis of death risks for patients. Nephrol Dial Transplant 19:2823-2830, 2004

300. Robinson BM, Feldman HI, Kobrin SM: Dialyzer reuse, in Nissenson AR, Fine RN (eds): Clinical Dialysis (ed 4). New York, NY, McGraw-Hill, 2005, pp 274-291

301. Kaufman AM, Levin NW: Dialyzer reuse, in Daugirdas J, Blake PG, Ing TS (eds): Handbook of Dialysis (ed 3). Philadelphia, PA, Lippincott Williams & Wilkins, 2001, pp 169-181

302. Murthy BV, Pereira BJ: Effects of reuse on dialyzer function. Semin Dial 13:282-286, 2000

303. Petersen J, Jani A: Effects of reuse on dialyzer function. Semin Dial 13:289-290, 2000

304. Fan Q, Liu J, Ebben JP, Collins AJ: Reuse-associated mortality in incident hemodialysis patients in the United States, 2000 to 2001. Am J Kidney Dis 46:661-668, 2005

305. Collins AJ, Ma JZ, Constantini EG, Everson SE: Dialysis unit and patient characteristics associated with reuse practices and mortality: 1989-1993. J Am Soc Nephrol 9:2108-2117, 1998

306. Sherman RA, Cody RP, Rogers ME, Solanchick JC: The effect of dialyzer reuse on dialysis delivery. Am J Kidney Dis 24:924-926, 1994

307. Farrell PC, Eschbach JW, Vizzo JE, Babb AL: Hemodialyzer reuse: Estimation of area loss from clearance data. Kidney Int 5:446-450, 1974

308. Garred LJ, Canaud B, Flavier JL, Poux C, Polito-Bouloux C, Mion C: Effect of reuse on dialyzer efficacy. Artif Organs 14:80-84, 1990

309. Murthy BV, Sundaram S, Jaber BL, Perrella C, Meyer KB, Pereira BJ: Effect of formaldehyde/bleach reprocessing on in vivo performances of high-efficiency cellulose and high-flux polysulfone dialyzers. J Am Soc Nephrol 9:464-472, 1998

310. Cheung AK, Agodoa LY, Daugirdas JT, et al: Effects of hemodialyzer reuse on clearances of urea and beta2-microglobulin. The Hemodialysis (HEMO) Study Group. J Am Soc Nephrol 10:117-127, 1999

311. Delmez JA, Weerts CA, Hasamear PD, Windus DW: Severe dialyzer dysfunction undetectable by standard reprocessing validation tests. Kidney Int 36:478-484, 1989

312. Deane N, Bemis JA: Multiple Use of Hemodialyzers (a report to the National Institute of Arthritis, Diabetes, Digestive and Kidney Disease). New York, NY, Manhattan Kidney Center, 1981

313. Gotch FA: Solute and water transport and sterilant removal in reused dialyzers, in Deane N, Wineman RJ, Bemis JA (eds): Guide to Reprocessing of Hemodialyzers. Boston, MA, Nijhoff, 1986, pp 39-61

314. Dialyzers transport properties and germicidal elution, in Seminar on the Reuse of Hemodialyzers and Automated and Manual Methods. New York, NY, National Nephrology Foundation, 1984

315. Krivitski NM, Kislukhin VV, Snyder JW, et al: In vivo measurement of hemodialyzer fiber bundle volume: Theory and validation. Kidney Int 54:1751-1758, 1998

316. Narsipur SS: Measurement of fiber bundle volume in reprocessed dialyzers. Clin Nephrol 61:130-133, 2004

317. Di Filippo S, Manzoni C, Andrulli S, et al: How to determine ionic dialysance for the online assessment of delivered dialysis dose. Kidney Int 59:774-782, 2001

318. Steil H, Kaufman AM, Morris AT, Levin NW, Polaschegg HD: In vivo verification of an automatic noninvasive system for real time Kt evaluation. ASAIO J 39:M348-M352, 1993

319. Lindsay RM, Bene B, Goux N, Heidenheim AP, Landgren C, Sternby J: Relationship between effective ionic dialysance and in vivo urea clearance during hemodialysis. Am J Kidney Dis 38:565-574, 2001

320. Mercadal L, Ridel C, Petitclerc T: Ionic dialysance: Principle and review of its clinical relevance for quantification of hemodialysis efficiency. Hemodial Int 9:111-119, 2005

321. Petitclerc T, Bene B, Jacobs C, Jaudon MC, Goux N: Non-invasive monitoring of effective dialysis dose delivered to the haemodialysis patient. Nephrol Dial Transplant 10:212-216, 1995

322. Rahmati MA, Rahmati S, Hoenich N, et al: On-line clearance: A useful tool for monitoring the effectiveness of the reuse procedure. ASAIO J 49:543-546, 2003

323. Gotch FA: On-line clearance: Advanced methodology to monitor adequacy of dialysis at no cost, in Ronco C, La Greca G (eds): Hemodialysis Technology. Basel, Switzerland, Karger, 2002, pp 268-271

324. Ing TS, Daugirdas JT: Extractable ethylene oxide from cuprammonium cellulose plate dialyzers: Importance of potting compound. ASAIO Trans 32:108-110, 1986

325. Ronco C, Levin NW, Polaschegg HD: Technical problems during hemodialysis, in Nissenson AR, Fine RN (eds): Dialysis Therapy (ed 3). Philadelphia, PA, Hanley & Belfus, 2002, pp 156-165

326. Cheung AK, Leypoldt JK: The hemodialysis membranes: A historical perspective, current state and future prospect. Semin Nephrol 17:196-213, 1997

327. Craddock PR, Fehr J, Dalmasso AP, Brighan KL, Jacob HS: Hemodialysis leukopenia. Pulmonary vascular leukostasis resulting from complement activation by dialyzer cellophane membranes. J Clin Invest 59:879-888, 1977

328. Himmelfarb J, Hakim RM: Biocompatibility and risk of infection in haemodialysis patients. Nephrol Dial Transplant 9:S138-S144, 1994 (suppl 2)

329. Lonnemann G: Should ultra-pure dialysate be mandatory? Nephrol Dial Transplant 15:S55-S59, 2000 (suppl 1)

330. Smollich BP, Falkenhagen D, Schneidewind J, Mitzner S, Klinkmann H: Importance of endotoxins in high-flux dialysis. Nephrol Dial Transplant 6:S83-S85, 1991 (suppl 3)

331. Lonnemann G, Koch KM: Beta(2)-microglobulin amyloidosis: Effects of ultrapure dialysate and type of dialyzer membrane. J Am Soc Nephrol 13:S72-S77, 2002 (suppl 1)

332. Schindler R, Linnenweber S, Schulze M, et al: Gene expression of interleukin-1 beta during hemodialysis. Kidney Int 43:712-721, 1993

333. Churchill DN: Clinical impact of biocompatible dialysis membranes on patient morbidity and mortality: An appraisal of the evidence. Nephrol Dial Transplant 10:S52-S56, 1995 (suppl 10)

334. Hakim RM, Held PJ, Stannard DC, et al: Effect of the dialysis membrane on mortality of chronic hemodialysis patients. Kidney Int 50:566-570, 1996

335. Hornberger JC, Chernew M, Petersen J, Garber AM: A multivariate analysis of mortality and hospital admissions with high-flux dialysis. J Am Soc Nephrol 3:1227-1237, 1992

336. Bonomini V, Coli L, Scolari MP, Stefoni S: Structure of dialysis membranes and long-term clinical outcome. Am J Nephrol 15:455-462, 1995

337. Bergamo Collaborative Dialysis Study Group: Acute intradialytic well-being: Results of a clinical trial comparing polysulfone with cuprophan. Kidney Int 40:714-719, 1991

338. Skroeder NR, Jacobson SH, Lins LE, Kjellstrand CM: Biocompatibility of dialysis membranes is of no importance for objective or subjective symptoms during or after hemodialysis. ASAIO Trans 36:M637-M639, 1990

339. Chenoweth DE: Complement activation during hemodialysis: Clinical observations, proposed mechanisms, and theoretical implications. Artif Organs 8:281-290, 1984

340. Ivanovich P, Chenoweth DE, Schmidt R, et al: Symptoms and activation of granulocytes and complement with two dialysis membranes. Kidney Int 24:758-763, 1983

341. Chanard J: [Membrane biocompatibility in dialysis: The role of absorption]. Nephrologie 24:359-365, 2003

342. Chanard J, Caudwell V, Valeire J, et al: Kinetics of 131I-beta2 microglobulin in hemodialysis patients: Assessment using total body counting. Artif Organs 22:574-580, 1998

343. Acchiardo S, Kraus AP Jr, Jennings BR: Beta 2-microglobulin levels in patients with renal insufficiency. Am J Kidney Dis 13:70-74, 1989

344. Hoenich NA, Woffindin C, Matthews JN, Goldfinch ME, Turnbull J: Clinical comparison of high-flux cellulose acetate and synthetic membranes. Nephrol Dial Transplant 9:60-66, 1994

345. Mrowka C, Schiffl H: Comparative evaluation of beta 2-microglobulin removal by different hemodialysis membranes: A six-year follow-up. Nephron 63:368-369, 1993

346. Zingraff J, Beyne P, Urena P, et al: Influence of haemodialysis membranes on beta 2-microglobulin kinetics: In vivo and in vitro studies. Nephrol Dial Transplant 3:284-290, 1988

347. Kuchle C, Fricke H, Held E, Schiffl H: High-flux hemodialysis postpones clinical manifestation of dialysis-related amyloidosis. Am J Nephrol 16:484-488, 1996

348. Koda Y, Nishi S, Miyazaki S, et al: Switch from conventional to high-flux membrane reduces the risk of carpal tunnel syndrome and mortality of hemodialysis patients. Kidney Int 52:1096-1101, 1997

349. Cheung AK, Rocco MV, Yan G, et al: Serum beta-2 microglobulin levels predict mortality in dialysis patients: Results of the HEMO Study. J Am Soc Nephrol 17:546-555, 2006

350. Ivanovich P, Rosner K: A case for cellulosic membrane hemodialyzers. Semin Dial 13:409-411, 2000

351. Chandna SM, Farrington K: Residual renal function: Considerations on its importance and preservation in dialysis patients. Semin Dial 17:196-201, 2004

352. Ward RA: Ultrapure dialysate. Semin Dial 17:489-497, 2004

353. Devoy MA, Tomson CR, Edmunds ME, Feehally J, Walls J: Deterioration in renal function associated with angiotensin converting enzyme inhibitor therapy is not always reversible. J Intern Med 232:493-498, 1992

354. James SH, Meyers AM, Milne FJ, Reinach SG: Partial recovery of renal function in black patients with apparent end-stage renal failure due to primary malignant hypertension. Nephron 71:29-34, 1995

355. Kuno T, Matsumoto K: Clinical benefit of preserving residual renal function in patients after initiation of dialysis. Blood Purif 22:S67-S71, 2004 (suppl 2)

356. Chavers BM, Li S, Collins AJ, Herzog CA: Cardiovascular disease in pediatric chronic dialysis patients. Kidney Int 62:648-653, 2002

357. Sarnak MJ, Levey AS: Cardiovascular disease and chronic renal disease: A new paradigm. Am J Kidney Dis 35:S117-S131, 2000 (suppl 1)

358. Reynolds JM, Morton MJ, Garralda ME, Postlethwaite RJ, Goh D: Psychosocial adjustment of adult survivors of a paediatric dialysis and transplant programme. Arch Dis Child 68:104-110, 1993

359. Fischbach M, Edefonti A, Schroder C, Watson A: Hemodialysis in children: General practical guidelines. Pediatr Nephrol 20:1054-1066, 2005

360. Gotch FA: Kinetic modeling in hemodialysis, in Nissenson AR, Fine RN, Gentile DE (eds): Clinical Dialysis. Norwalk, CT, Appleton and Lange, 1995, pp 156-188

361. Yeun JY, Depner TA: Principles of hemodialysis, in Pereira BJ, Sayegh MH, Blake P (eds): Chronic Kidney Disease, Dialysis, and Transplantation. Philadelphia, PA, Elsevier Saunders, 2005, pp 307-340

362. Depner TA: Prescribing Hemodialysis: A Guide to Urea Modeling. Boston, MA, Kluwer, 1991

363. Sargent JA, Gotch FA: Mathematic modeling of dialysis therapy. Kidney Int 18:S2-10, 1980 (suppl 10)

364. Depner TA, Greene T, Gotch FA, Daugirdas JT, Keshaviah PR, Star RA: Imprecision of the hemodialysis dose when measured directly from urea removal. Hemodialysis Study Group. Kidney Int 55:635-647, 1999